Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats

World Journal of Surgery
K MotoyamaM Tanaka

Abstract

It has been shown that pretransplant intrathymic injection of donor antigen prolongs rat cardiac allograft survival. The purpose of the present study was to evaluate whether co-administration of FK506 could enhance the beneficial effect of intrathymic preimmunization; we also wished to clarify whether this combined treatment could be effective for renal allografts. Seven days prior to transplantation 5 x 10(7) donor splenocytes were injected into the thymus of LEW (RT1l) recipients of WKA (RT1u) cardiac or renal allografts. Using a miniosmotic pump, FK506 was administered for 7 days before transplantation at a dose of 3 mg/kg/day. Whereas intrathymic injection of donor splenocytes or subcutaneous FK506 alone showed limited (15.2 days) or no (7.3 days) prolongation of cardiac allograft survival, the combined treatment with these two modalities synergistically prolonged the survival of the cardiac allograft (> 82.0 days). This combined treatment, however, failed to prolong renal allograft survival (8.4 days). Although donor-specific prolongation of a second cardiac allograft was obtained in LEW rats with a well beating WKA heart, two of the three recipients ultimately rejected both first and second WKA cardiac allografts. Additio...Continue Reading

References

Oct 1, 1992·Current Opinion in Immunology·J J Siekierka, N H Sigal
Jul 4, 1990·JAMA : the Journal of the American Medical Association·T E StarzlM Alessiani
Sep 1, 1990·Annals of Surgery·S TodoR Shapiro
Oct 28, 1989·Lancet·T E StarzlA Jain
Dec 21, 1989·The New England Journal of Medicine·B D Kahan
Jan 1, 1985·Urological Research·C P SavasM Fox

❮ Previous
Next ❯

Citations

Jul 25, 2012·Surgical Neurology International·Andres R Plasencia, Alejandro Santillan
Nov 5, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Thomas HaudebourgBernard Vanhove

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.